Results 91 to 100 of about 10,024 (235)
Clinical and Translational Science, 2023 Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A
Marian Iwamoto +10 more
doaj +1 more source
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study [PDF]
, 2023 Background Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause mortality in community-dwelling COVID-19 patients treated with these drugs ...
Erne, Elke Maria +4 more
core +1 more source
Emerging Microbes and InfectionsLimited studies compared the effectiveness of nirmatrelvir/ritonavir and molnupiravir against a control group on post-COVID-19 conditions. Our study examined the association of nirmatrelvir/ritonavir and molnupiravir with post-acute mortality and ...
Yuchen Wei +18 more
semanticscholar +1 more source
Reviews in Medical Virology, Volume 36, Issue 2, March 2026.ABSTRACT Small randomized controlled trials (RCTs) in COVID‐19 meta‐analyses have been associated with more favourable treatment effects and reduced result stability. This study assessed how trial size impacts effect estimates, statistical stability, and risk of bias.
Dong Hyun Kim +11 more
wiley +1 more source
Science Translational Medicine, 2021 There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression to severe coronavirus disease 2019 (COVID-19).
W. Fischer +18 more
semanticscholar +1 more source
ChemMedChem, Volume 21, Issue 4, 25 February 2026.Schematic representation depicting the influence of phosphine ligand identity on the biological and physicochemical characteristics of Pt(II) complexes: PTA promotes antileishmanial activity, PPh2(Php–COOH) strengthens antiviral activity, and TCEP enhances fluorescence.
Antonio A. de Oliveira‐Neto +12 more
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 515-524, February 2026.Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya +5 more
wiley +1 more source
Molnupiravir in unvaccinated patients with COVID-19 [PDF]
Drug and Therapeutics Bulletin, 2022 Abstract Overview of: Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. NEJM. 2021;doi:10.1056/NEJMoa2116044 [Epub ahead of print 16 Dec 2021].
openaire +2 more sources
Asian Journal of Pharmaceutical and Clinical ResearchObjectives: The objective of this study was to establish a rapid and sensitive ultra-performance liquid chromatography (UPLC) method for the simultaneous estimation of molnupiravir and favipiravir in rat plasma using nirmatrelvir as internal reference ...
GOPE EDWARD RAJU +2 more
semanticscholar +1 more source
Health Science Reports, Volume 9, Issue 2, February 2026.ABSTRACT Background and Aims The COVID‐19 pandemic has posed significant challenges for individuals with obstructive pulmonary diseases (OPDs), such as asthma and chronic obstructive pulmonary disease (COPD). Emerging evidence highlights the complex interplay between SARS‐CoV‐2 infection and OPDs, including increased risks of severe disease, long‐term ...
Behnam Dalfardi +6 more
wiley +1 more source